

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 to 70. (Cancelled)

71. (Currently amended): A composition containing a nucleic acid sequence encoding a polypeptide consisting of SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

72. (Currently amended): A composition containing a nucleic acid sequence encoding a polypeptide ~~that comprises the sequence of~~ comprising SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

73. (Currently amended): A composition containing a nucleic acid sequence that encodes a polypeptide comprising a peptide sequence at least 98% identical to the 1132 residues of SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

74. (Currently amended): A composition containing a nucleic acid sequence encoding a polypeptide consisting of at least 10 contiguous amino acids of SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

75. (Cancelled)

76. (Currently amended): A composition containing a nucleic acid sequence encoding a polypeptide that comprises at least 10 contiguous amino acids of SEQ. ID NO:2, wherein said

nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

77. (Currently amended): A composition containing a nucleic acid sequence encoding a polypeptide selected from:

- (a) the amino acid sequence SEQ ID NO:2; and,
- (b) an immunogenic fragment of SEQ ID NO:2,

wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition, when administered to a subject, induces an adaptive immune response against hTRT (SEQ ID NO:2).

78. (Cancelled)

79. (Currently amended): A composition containing a plasmid vector encoding a polypeptide that comprises ~~the sequence of~~ SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2) ~~when administered to a subject~~.

80. (Currently amended): A composition containing a plasmid vector encoding a polypeptide that comprises at least 10 contiguous amino acids of SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2) ~~when administered to a subject~~.

81. (Currently amended): A composition containing a plasmid vector encoding a polypeptide comprising a sequence identical to the 1132 residues of SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2) ~~when administered to a subject~~.

82. (Currently amended): A composition containing a plasmid vector encoding a polypeptide comprising a peptide sequence at least 98% identical to the 1132 residues of SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2) ~~when administered to a subject~~.